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Ltd. This is an open access article unAbstract The majority of patients with head and neck cutaneous squamous cell carcinoma
(cSCC) are successfully treated with surgical treatment of the primary site. While only a minor-
ity of patients is at risk for regional metastasis, these patients have significantly worse out-
comes. Tumor and patient factors that place patients at high risk for development of
regional metastasis have been identified. Advancing treatment of cSCC requires identifying
and escalating treatment in this high risk patient population, while avoiding overtreatment
of the majority of cSCC patients that do not develop regional metastasis. Sentinel lymph node
biopsy has emerged as a promising technique in cSCC to detect micrometastasis and allow
early surgical treatment of regional disease. Future directions involve genomic characteriza-
tion of metastatic and nonmetastatic cSCC to identify genomic alterations causing metastasis
that may be used to predict disease behavior.
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Cutaneous squamous cell carcinoma (cSCC) is the second
most common cancer diagnosed in the USA annually with
approximately 700,000 cases of cSCC each year. Exposure to
ultraviolet radiation is the most important risk factor for
development of cSCC.1 Most patients with cSCC elicit a his-
tory of prolonged lifetime sunlight exposure, and history of
severe sunburns are a critical risk factor.2 Ultraviolet radia-
tion typically produces the formation of thymidine dimers innd hosting by Elsevier B.V. on behalf of KeAi Communications Co.,
://creativecommons.org/licenses/by-nc-nd/4.0/).
High risk cutaneous squamous cell carcinoma 137the p53 tumor-suppressor gene and failure to recognize and
repair these mutations results in development of cSCC.1
Only a minority of patients with cSCC will develop
regional metastasis and subsequently require treatment to
the regional lymph node basin. The classic number that is
commonly cited regarding the percentage of patients that
develop regional metastasis is 5%.1,3,4 As such, the majority
of patients with cSCC can be successfully treated with
surgical excision and Mohs’ micrographic surgery. However,
the rate of regional metastasis may be as high as 21% in
tertiary care centers.5 In these patients, development of
regional metastasis results in 3-year disease free survival
rate of 56% and 5-year overall survival of 25%e35%4,6,7; 10-
year overall survival is less than 20%.1
Identifying patients with cSCC at risk for regional
metastasis and delivering early, therapeutic treatment to
the regional lymph node basin in this patient population is
critical. Importantly, the majority of patients with cSCC do
not develop regional metastasis, and it is paramount to
avoid overtreating this patient population. This article re-
views critical data and articles that have advanced the
management of head and neck cSCC and in particular, the
high risk patient with cSCC.Table 1 AJCC staging system for cutaneous squamous cell
carcinoma.
AJCC tumor staging system for cSCC
T classification
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor 2 cm in greatest dimension with <2 high-risk
features
T2 Tumor >2 cm in greatest dimension or any size with 2
high-risk features
T3 Tumor with invasion of maxilla, mandible, orbit, or
temporal bone
T4 Tumor with invasion of skeleton (axial or appendicular)
or perineural invasion of skull base
N classification
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm
N2 Metastasis in a single ipsilateral lymph node, >3 cm
but 6 cm in greatest dimension; or in bilateral or
contralateral lymph nodes, none greater than 6 cm
N2a Metastasis in a single ipsilateral lymph node >3 cm but
6 cm
N2b Metastasis in multiple ipsilateral lymph nodes, none
>6 cm
N2c Metastasis in bilateral or contralateral lymph nodes,
none >6 cm
N3 Metastasis in a lymph node >6 cm in greatest
dimensionDefining the “high risk” population
Brantsch et al.8 prospectively analyzed 615 patients with
cSCC, analyzing factors predicting regional lymph node
metastasis. In this study, all patients were treated with sur-
gical excision and confirmed negative margins. They were
subsequently followedevery 6months for2 years, followedby
surveillanceevery 24months.Mean andmedian followupwas
43 months, and 26 patients (4%) developed regional metas-
tasis. Brantsch et al.8 identified 4 key prognostic factors on
multivariate analysis predictive of regional metastasis:
1. Increased tumor thickness (HR 4.79)
2. Localization at the ear (HR 3.61)
3. Increased tumor diameter (HR 2.22)
4. Presence of immunosuppression (HR 4.32)
Specifically, increased tumor thickness showed a hazard
ratio of 4.79. Importantly, patients in this series with
2.0 mm thickness or less never developed regional metas-
tasis. In contrast, 16% of patients with greater than 6.0 mm
thickness developed regional metastasis and 3.8% of pa-
tients with intermediate tumor thickness of 2.1e6.0 mm
developed regional metastasis. Localization at the ear
resulted in a hazard ratio of 3.61 as 10% of patients with
primary ear cSCC developed regional metastasis. Similar to
tumor thickness, increasing tumor diameter resulted in
greater metastatic potential; patients with tumors 2 cm or
less in diameter metastasized less than 2% of the time. In
contrast, tumor diameter greater than 5.0 cm metastasized
20% of the time, and those with intermediate tumor
diameter 2.1e5.0 cm metastasized 8% of the time. Finally,
presence of immunosuppression resulted in a hazard ratio
of 4.32, with 16% of immunosuppressed patients developing
regional metastasis. Findings from the Bransch study sug-
gest that tumor size (thickness and diameter) are important
features in metastasis prediction.Veness9 published a review article highlighting several
other high risk features: incomplete excision/recurrence,
poor differentiation, location on lip and/or drainage to the
parotid basin, perineural and lymphovascular invasion.3,10
TNM staging
American Joint Committee on Cancer (AJCC) TNM staging
classification11 for cSCC was updated in 2010 and is shown
in Table 1. The latest update added several high risk fea-
tures to the T classification staging system and sub-
classified nodal staging into 5 categories (N1, N2a, N2b,
N2c, and N3). Previously, nodal staging was either positive
(N1) or negative (N0).
Despite these changes, the TNM classification system
continues to have significant weaknesses.12 For example,
consider Patient #1, who has a 2.5 cm well differentiated
cSCC on the frontal scalp, 1 mm depth of invasion, no
perineural or lymphovascular invasion, no palpable lymph-
adenopathy, and no history of immunosuppression. On the
other hand, consider Patient #2, who has a 4.0 cm poorly
differentiated cSCC on the right ear, 5 mm depth of inva-
sion, with perineural and lymphovascular invasion, with a
history of renal transplantation and immunosuppression,
but no palpable lymphadenopathy. Based on the current
staging system, both of these patients would be staged as
T2 N0 M0 (Fig. 1) despite distinct risk profiles for recurrence
and regional adenopathy.12 Furthermore, Brunner et al.13
138 S.Y. Kang, A.E. Tolandshowed no difference in survival between the newly
designated N1 and N2 subgroups, while patients with N3
disease had significantly worse overall survival.
Treatment
The primary treatment options for cSCC of the head and
neck are surgical excision and Mohs micrographic surgery.
The optimal treatment modality depends on the tumor
location, stage, comorbidities, and patient choice. Mohs
micrographic surgery provides a 97.4% local control rate14
while preserving as much normal tissue as possible. The
downside of Mohs micrographic surgery is the additional
time required as well as a significant increase in cost.15
Furthermore, in high risk cases, sentinel lymph node bi-
opsy cannot be performed in lesions undergoing Mohs mi-
crographic surgery. It is important to note that while both
methods are considered standard of care in the manage-
ment of cSCC, there is no data to support superiority of
Mohs micrographic surgery or standard surgical excision.
Surgical margins are dependent on the relative risk of
local recurrence. There is a lack of recent data regarding
surgical margins in cSCC. One frequently cited study stated
that obtaining a 4 mm margin for lesions with a diameter of
2 cm or less would result in a 95% negative margin rate, and
a 6 mm margin for lesions with a diameter of greater than
2 cm.16 While 1 cm margins are recommended for lesions
>2 cm,17 this can be difficult to achieve in cosmetically
sensitive subsites. These authors recommend 4e6 mm
margins for low risk cSCC, and 1 cm margins for tumors
exhibiting high risk features.17 In the setting of positive
margins, re-resection is recommended.17 Radiation treat-
ment is typically reserved for adjuvant treatment but can
be used in cases where surgery is contraindicated or margin
clearance is not possible.17
Sentinel node biopsy in the N0 neck
Gore et al.18 published the largest series of sentinel lymph
node biopsy (SLNB) in head and neck cSCC. This studyFig. 1 In the current staging system, two patients with distinct ris
the same TNM stage classification.included 57 patients, all of whom had at least one of the
following high risk features: tumor size >2 cm, invasion into
subcutaneous fat or tumor thickness >5 mm, poor differen-
tiation, perineural invasion/lymphovascular invasion, local
recurrence in setting of adequate initial resection, ear or lip
location, immunosuppressed, and carcinoma arising in a
preexisting scar. In this population, 12.3% of patients had a
positive sentinel lymph node biopsy, leading to immediate
therapeutic neck dissection. In the patients undergoing neck
dissection, 20% had additional nodal disease identified by
neck dissection. There were two regional recurrences, one
patient who had a positive sentinel node, immediate thera-
peutic neck dissection, and adjuvant radiation treatment,
and one patient who could not undergo SLNB because the
sentinel node could not be identified by lymphoscintigraphy
or by neck exploration. Thus, the false negative rate SLNB in
this series was 0%. Perineural invasion, lymphovascular in-
vasion, and number of high risk factors were predictors of
regional metastasis. As expected, patients with positive
SLNB had significant worse disease specific survival as
compared to those with negative SLNB.
Gore et al.18 pooled the SLNB in head and neck for cSCC
in the existing literature, citing 82 cases19e22 with a 10%
SLNB positivity rate and 98% negative predictive value.
This, along with their series, suggests that SLNB for head
and neck cSCC is a feasible, accurate staging procedure
that carries significant prognostic information. However,
more data are needed to answer the critical question of
whether early intervention in patients with micro-
metastatic disease and positive SLNB in the form of im-
mediate therapeutic neck dissection provides survival
benefit over observation and delayed therapeutic neck
dissection.Management of the ND neck
Patients that present with palpable cervical lymphade-
nopathy or parotid disease should undergo upfront, thera-
peutic selective neck dissection and/or parotidectomy.23
The authors recommend dissection of the clinicallyk profiles for recurrence and regional metastasis are placed into
High risk cutaneous squamous cell carcinoma 139involved nodal basin and those nodal basins at risk given the
location of the cSCC. For anterior lesions of the face, the
superficial parotid and levels IeIV are at risk for nodal
involvement.23 For posterior lesions of the scalp, the
postauricular, suboccipital, and levels IIeV at risk.23 The
authors, as a general guideline, use the coronal plane of the
external ear canal to divide the at risk nodal basin to an
anterior field including the superficial parotid and levels
IeIV, and a posterior field involving postauricular and sub-
occipital lymph nodes as well as levels IIeV. It remains
critical to always resect the external jugular lymph node
chain, which is at high risk for nodal spread.24 Patients
presenting with a parotid metastasis have a 30% chance of
harboring cervical neck metastases,24 so the cervical lymph
node basin should always be treated either with selective
neck dissection or adjuvant radiation treatment when pa-
rotid lymph nodes are involved.Adjuvant treatment
While there are no universally adopted guidelines for
adjuvant treatment in cSCC,17 commonly accepted in-
dications for adjuvant radiation treatment include two or
more positive lymph nodes, extracapsular spread, lymph
nodes greater than 3 cm in size, perineural invasion, dermal
or in transit metastases, bone invasion, and close or posi-
tive margins.17,23Future directions: MicroRNA, epigenetic
alterations, and next-generation sequencing
Basic science research in the field of tumor metastasis has
illuminated the molecular basis of metastasis. The meta-
static cascade by which tumor cells detach from the pri-
mary tumor and enter the lymphatic or circulatory system,
survive during transport, and proliferate at regional or
distant sites, requires an exquisite coordination of tempo-
ral gene expression.25 Noncoding regulatory RNA genes,
known as microRNA (miRNA), have been identified as key
regulators of tumor metastasis, having pro-metastatic and
anti-metastatic effects.25 Ma et al. reported the first miRNA
related to metastasis promotion in breast cancer, identi-
fying miR-10b as a metastasis promoter in breast cancer.9
Identification of miRNAs in cSCC that promote tumor
metastasis has tremendous potential for clinical trans-
lation, as these markers would be highly useful for prog-
nosis, risk stratification of metastatic disease, and
potential targeted therapies.26
Gillespie et al.27 investigated microRNA (miRNA)
expression in metastatic cSCC relative to non-metastatic
primary cSCC to identify candidates for targeted therapy
and/or biomarkers that predict metastasis. miRNA
expression analysis was performed in non-metastatic pri-
mary cSCC and in metastatic cSCC at the primary site and
the regional lymph node. Expression of multiple miRNAs
showed significant differences at the regional lymph node
metastasis versus the primary cSCC, with up-regulation of
miR-4286, miR-200a-3p and miR-148-3p and down-
regulation of miR-1915-3p, miR-205-5p, miR-4516 and
miR-150-5p, suggesting that these may be usefulpredictors of regional metastasis or represent therapeutic
targets.
Epigenetic modifications are also known to play a role in
tumor metastasis.28 Darr et al.28 investigated epigenetic
profiles of metastatic and non-metastatic cSCC to identify
unique patterns that may predict the development of
metastatic cSCC. While widespread differences in methyl-
ation patterns were not seen, distinct epigenetic profiles
were identified in the promoter region of FRZB in meta-
static cSCC compared to their non-metastatic counterparts
and this site represented the most differentially methyl-
ated site. FRZB, a known regulator of bone development,
was found to be extensively hypermethylated in metastatic
(median methylation: 46.7%) versus non-metastatic cSCC
(median methylation 4.7%). Methylation of FRZB has also
been associated with worse outcomes in bladder cancer,29
and these results suggest that in cSCC, FRZB may repre-
sent a biomarker of the metastatic phenotype.
Li et al.30 performed next generation sequencing on
cSCC lymph node metastases to identify recurrent patterns
of genomic alterations that may lead to new clinical trials
and therapeutic agents. In this study of 29 patients that
developed metastatic cSCC, 11 patients exhibited recur-
rence within an average of 24 months. However the time to
recurrence ranged from 1 to 78 months, while other pa-
tients remained recurrence free at 130 months, empha-
sizing the heterogeneous nature of this cohort of patients
with metastatic cSCC and the need for advancing treatment
options in this patient population. Next generation
sequencing identified a heterogenous degree of genomic
alterations and mutations were recurrently identified
across the entire cohort in four major categories: RAS/RTK/
PI3K, squamous differentiation, cell cycle, and chromatin
remodeling pathway gene pathways. The top three altered
genes were TP53, CDKN2A, and NOTCH1/2/4. No single
gene significantly predicted survival which is unsurprising as
these genes are frequently mutated in all SCCs. However,
oncogenic alterations activating the RAS/RTK/PI3K
pathway, which were present in 45% of samples, were
significantly correlated with worse progression free sur-
vival. Numerous tumors exhibited activating mutations of
receptor tyrosine kinases, downstream kinases, and genes
in the PI3K/AKT pathway, suggesting that agents currently
under investigation in other cancer sites (MEK, mTOR,
FGFR, BRAF, PI3K inhibitors) should be considered in this
population of patients with metastatic cSCC.30Conclusions
Surgical excision remains the mainstay of treatment of
cutaneous squamous cell carcinoma, whether by Mohs mi-
crographic surgery or standard surgical resection. While the
majority of patients are cured with local surgical excision, a
subset of patients is at high risk for developing recurrence
and regional lymph node metastasis. Clinical features
placing patients at high risk for regional metastasis such as
size and perineural invasion have been established. These
patients may be ideal candidates for sentinel lymph node
biopsy, although the survival impact of SLNB and early
therapeutic neck dissection versus observation of the neck
and delayed neck dissection remains to be seen. Future
140 S.Y. Kang, A.E. Tolanddirections involve the use of next-generation sequencing
and microRNA analysis to identify biomarkers that predict
development of regional metastasis that may guide upfront
treatment and provide therapeutic targets for adjuvant
treatment.
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